Drug Profile
Morphine/phenylephrine/sorbitol
Alternative Names: BL-3010Latest Information Update: 29 Sep 2015
Price :
$50
*
At a glance
- Originator Gevys Pharmaceuticals
- Developer BioLineRx
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 29 Sep 2015 No recent reports on development identified - Phase-I/II for Pain (In volunteers) in Israel (PO)
- 07 May 2007 BL 3010 is still undergoing phase I/II development.
- 30 Sep 2006 Phase-I/II clinical trials in Pain (In volunteers) in Israel (PO)